



January 31, 2025
JCR Pharmaceuticals Co., Ltd.

Revision of Consolidated Financial Forecasts for Fiscal Year Ended March 31, 2025

Jan. 31, 2025 -- [JCR Pharmaceuticals Co., Ltd.](http://www.jcr-pharm.co.jp) (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced today that the Company made the following revisions to the consolidated earnings forecasts for the fiscal year ended March 31, 2025 disclosed on May 10, 2024 (at the time of the financial results announcement) based on the current business performance.

There are no changes to the previously announced dividend forecast.

1. Revision of consolidated financial forecasts for the fiscal year ended March 31, 2025

(Unit: Millions of yen)

	Net Sales	Operating profit	Ordinary profit	Profit attributable to owners of parent	Earnings per share (yen)
Previously announced forecasts (A)	41,300	5,400	4,600	3,700	29.65
Revised forecasts (B)	39,000	1,400	750	2,200	17.77
Change (B-A)	(2,300)	(4,000)	(3,850)	(1,500)	—
Change (%)	(5.6) %	(74.1) %	(83.7) %	(40.5) %	—
Actual Results of the previous fiscal year	42,871	7,531	7,264	5,507	44.13

2. Reason for the revision

Net sales have been revised to 39,000 million yen, down 2,300 million yen from the previous forecast. While product sales remain largely on track, income from contractual payment was revised downward because an overseas licensing agreement will not be concluded for JR-171 within this fiscal year. The revised break-down of sales forecast is <Appendix 1> below.

Despite improvements in cost efficiency and a favorable product mix, higher disposal costs for manufacturing materials are expected. Accordingly, the cost of sales have increased by 700 million yen from the previous forecast.

Expenses were increased by 400 million yen allocated to selling, general and administrative expenses, and 600 million yen to R&D expenses, based on results until the third quarter, etc.

As a result, operating profit has been revised down by 4,000 million yen to 1,400 million yen. Ordinary profit was revised down by 3,850 million yen to 750 million yen, and net profit attributable to owners of the parent was reduced by 1,500 million yen to 2,200 million yen.

<Appendix 1>

The revised forecast breaks down of product sales.

(Unit: Millions of yen)

	Previously announced forecasts (A)	Revised forecasts (B)	Change (B-A)	Change (%)	(Reference) Actual results of the previous fiscal year
GROWJECT®	18,300	18,300	—	—	17,913
IZCARGO®	5,700	5,800	100	1.8 %	5,171
TEMCELL® HS Inj.	2,800	2,900	100	3.6 %	3,236
Treatments for renal anemia	4,200	3,700	(500)	(11.9) %	4,652
Epoetin Alfa BS Inj. [JCR]	2,200	1,700	(500)	(22.7) %	1,994
Darbepoetin Alfa BS Inj. [JCR]	2,000	2,000	—	—	2,658
Agalsidase Beta BS I.V. Infusion [JCR]	1,100	1,100	—	—	1,661
Total pharmaceutical products	32,100	31,800	(300)	(0.9) %	32,636
License Revenue	8,100	6,100	(2,000)	(24.7) %	7,413
Other	1,100	1,100	—	—	2,820
Total Net Sales	41,300	39,000	(2,300)	(5.6) %	42,871

Note: The forecasts above are based on information available as of the announcement date and are subject to change due to various factors.

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 49-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and belief – benefit all our stakeholders, including patients, partners, and employees. For more information, please visit <https://www.jcrpharm.co.jp/en/site/en/>.

Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

ir-info@jp.jcrpharm.com

###